Changes in anticonvulsant prescribing for Australian children: Implications for Quality Use of Medicines

Journal of Paediatrics and Child Health

Volumn 48, Issue 6, 2012, Pages 490-495

  Cohen, Simon A ^a   Lawson, John A ^a   Graudins, Linda V ^b   Pearson, Sallie A ^c   Gazarian, Madlen ^b  

^a SYDNEY CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

anticonvulsant; child; drug prescription; drug utilisation review; epilepsy; evidence based medicine

Indexed keywords

CARBAMAZEPINE; CLONAZEPAM; ETHOSUXIMIDE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; SULTIAME; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ADOLESCENT; AGING; ANTICONVULSANT THERAPY; ARTICLE; CHILD; CHILD HEALTH CARE; DRUG COST; DRUG UTILIZATION; EPILEPSY; FOCAL EPILEPSY; GRAND MAL SEIZURE; HEALTH CARE QUALITY; HUMAN; INFANT; LENNOX GASTAUT SYNDROME; MONOTHERAPY; OFF LABEL DRUG USE; OUTCOME ASSESSMENT; PHARMACEUTICAL CARE; PRACTICE GUIDELINE; PRESCHOOL CHILD; PRESCRIPTION; PRIORITY JOURNAL; SCHOOL CHILD; TONIC CLONIC SEIZURE;

ADOLESCENT; ANTICONVULSANTS; AUSTRALIA; CHILD; CHILD, PRESCHOOL; DRUG APPROVAL; DRUG COSTS; DRUG UTILIZATION REVIEW; EPILEPSY; HUMANS; INFANT; INFANT, NEWBORN; OFF-LABEL USE; PHYSICIAN'S PRACTICE PATTERNS;

EID: 84862763537     PISSN: 10344810     EISSN: 14401754     Source Type: Journal    
DOI: 10.1111/j.1440-1754.2011.02223.x     Document Type: Article

References (20)

1. Bergey G,. Evidence-based treatment of idiopathic generalized epilepsies with new antiepileptic drugs. Epilepsia 2005; 46: 161-8. (Pubitemid 44921995)
2. Goodkin H, Buck M,. Still orphans. Antiepileptic drug trials in children under 2 years of age. Neurology 2008; 70: 2093-4.
3. Gamble CL, Williamson PR, Marson AG,. Lamotrigine versus carbamazepine monotherapy for epilepsy. Cochrane Database Syst. Rev. 2006; 1: Art. No.: CD001031. DOI: 10.1002/14651858.CD001031.pub2.
4. Marson AG, Appleton R, Baker GA, et al,. A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. The SANAD trial. Health Technol. Assess. 2007; 11: 1-134.
5. Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, et al,. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006; 47: 1094-120. (Pubitemid 44086745)
6. National Institute For Clinical Excellence. Newer Drugs for Epilepsy in Children. Technology Appraisal Guidance 79. National Institute For Clinical Excellence, 2004. Available from: [accessed Jan 2011].
7. French JA, Kanner AM, Bautista J, et al,. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy. Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004; 62: 1252-60. (Pubitemid 38526035)
8. French JA, Kanner AM, Bautista J, et al,. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy. Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004; 62: 1261-73. (Pubitemid 38526036)
9. Neurology Expert Group. Therapeutic Guidelines: Neurology. Version 2. Melbourne: Therapeutic Guidelines Limited, 2007.
10. Gazarian M, Kelly M, McPhee JR, et al,. Off-label use of medicines: consensus recommendations for evaluating appropriateness. Med. J. Aust. 2006; 185: 544-8. (Pubitemid 44816941)
11. Gazarian M,. Why are children still therapeutic orphans? (Editorial). Aust. Prescr. 2003; 26: 122-3. (Pubitemid 37484558)
12. Gazarian M,. Off-label Use of Medicines in the Paediatric Population: Recommendations for Assessing Appropriateness. Discussion paper for consultation, 7 May 2007 (WHO Expert Consultation on Essential Medicines for Children, 9-13 July 2007, Geneva), 2007. Available from: [accessed Jan 2011].
13. Tsiropoulos B, Gichangi A, Andersen M, et al,. Trends in utilization of antiepileptic drugs in Denmark. Acta Neurol. Scand. 2006; 113: 405-11. (Pubitemid 44046326)
14. Savica R, Beghi E, Mazzaglia G, et al,. Prescribing patterns of antiepileptic drugs in Italy: a nationwide population-based study in the years 2000-2005. Eur. J. Neurol. 2007; 14: 1317-21. (Pubitemid 350135294)
15. Cohen S, Taitz J, Jaffé A,. Paediatric prescribing of asthma drugs in the UK: are we sticking to the guideline? Arch. Dis. Child. 2007; 92: 847-9. Epub 4 Sep 2007. (Pubitemid 47535439)
16. Lowinger J, Stark H, Kelly M, Hughes C, Gazarian M, Kaye K,. Improving medicines use with clinician-led use of validated clinical indicators (editorial). Med. J. Aust. 2010; 192: 180-1.
17. Gazarian M,. Delivering better medicines to children: need for better integration between the science, the policy and the practice. Paediatr. Drugs 2009; 11: 41-4.
18. Ackers R, Murray ML, Besag FMC, Wong ICK,. Prioritizing children's medicines for research: a pharmacoepidemiological study of antiepileptic drugs. Br. J. Clin. Pharmacol. 2007; 63: 689-97. (Pubitemid 46753576)
19. Australian Government Department of Health and Ageing. Schedule of pharmaceutical benefits web site. Available from: [accessed Jan 2011].
20. Gazarian M, Murray K, Roberton D,. Discontinuation of naproxen suspension (letter to editor). Aust. Prescr. 2002; 25: 106-7.